Hromic-Jahjefendic Altijana, Lundstrom Kenneth
Department of Genetics and Bioengineering, Faculty of Engineering and Natural Sciences, International University of Sarajevo, 71000 Sarajevo, Bosnia and Herzegovina.
PanTherapeutics, CH 1095 Lutry, Switzerland.
Biomedicines. 2020 Mar 16;8(3):60. doi: 10.3390/biomedicines8030060.
Gene therapy applications of oncolytic viruses represent an attractive alternative for cancer treatment. A broad range of oncolytic viruses, including adenoviruses, adeno-associated viruses, alphaviruses, herpes simplex viruses, retroviruses, lentiviruses, rhabdoviruses, reoviruses, measles virus, Newcastle disease virus, picornaviruses and poxviruses, have been used in diverse preclinical and clinical studies for the treatment of various diseases, including colon, head-and-neck, prostate and breast cancer as well as squamous cell carcinoma and glioma. The majority of studies have focused on immunotherapy and several drugs based on viral vectors have been approved. However, gene therapy for malignant melanoma based on viral vectors has not been utilized to its full potential yet. This review represents a summary of the achievements of preclinical and clinical studies using viral vectors, with the focus on malignant melanoma.
溶瘤病毒的基因治疗应用是癌症治疗的一种有吸引力的替代方法。多种溶瘤病毒,包括腺病毒、腺相关病毒、甲病毒、单纯疱疹病毒、逆转录病毒、慢病毒、弹状病毒、呼肠孤病毒、麻疹病毒、新城疫病毒、小RNA病毒和痘病毒,已被用于各种临床前和临床研究,以治疗包括结肠癌、头颈癌、前列腺癌和乳腺癌以及鳞状细胞癌和神经胶质瘤在内的各种疾病。大多数研究集中在免疫治疗,几种基于病毒载体的药物已获批准。然而,基于病毒载体的恶性黑色素瘤基因治疗尚未得到充分利用。本综述总结了使用病毒载体的临床前和临床研究成果,重点是恶性黑色素瘤。